ImmuCell names Olivier te Boekhorst as next president and CEO

ImmuCell Corporation (NASDAQ: ICCC) announced the selection of Olivier te Boekhorst as its next president and CEO, with an anticipated start date of November 1, 2025.

Te Boekhorst currently serves as an operating partner at ARCHIMED, a global investment firm focused on healthcare industries, and chairs the board of SeqCenter, a sequencing laboratory in Pittsburgh where he previously served as CEO. From 2004 to 2022, he held leadership roles at IDEXX Laboratories, where he led mergers and acquisitions activities in livestock diagnostics and served as senior vice president overseeing livestock and dairy diagnostics, water safety testing, and human diagnostics divisions.

Michael F. Brigham, ImmuCell's current president and CEO, will serve as special advisor to the CEO for at least two months following te Boekhorst's start date to facilitate the transition. Brigham will continue serving on the company's board of directors until the next annual meeting of stockholders.

The company granted te Boekhorst two initial stock option awards as inducement grants. The first award, granted September 16, 2025, consists of non-qualified stock options to purchase 76,673 shares at an exercise price of $5.90 per share. This award expires if te Boekhorst does not commence employment by November 30, 2025. A second award for up to 85,000 additional shares will be granted after employment begins, with an exercise price equal to the closing stock price on the grant date.

Both option grants carry 10-year terms and vest in three equal increments on the first, second, and third anniversaries of their respective grant dates.

ImmuCell develops and manufactures animal health products for dairy and beef cattle, including First Defense for newborn calves and Re-Tain for subclinical mastitis treatment in dairy cows.

You May Also Be Interested In

• Putin, Xi, Trump may hold trilateral talks at APEC summit - Russia's Vesti
• S&P Dow Jones Indices and Kaiko launch co-branded crypto index suite
• Daxor Corp. (DXR) PT Lowered to $18 at Lake Street